Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danai Dima

Showing results (111-120 of 161) with videos related to

Pageof 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2023
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T ConsortiumDoris K Hansen, Surbhi Sidana, Lauren C Peres, et al.
Transplantation and Cellular Therapy|September 19, 2025
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy ConsortiumKaren Sweiss, Charlotte Wagner, Eric Anto, et al.
Haematologica|October 19, 2023
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experienceHamza Hashmi, Doris K Hansen, Lauren C Peres, et al.
Journal of Hematology & Oncology|June 6, 2024
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucelSaurabh Zanwar, Surbhi Sidana, Leyla Shune, et al.
Haematologica|September 21, 2023
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairmentSurbhi Sidana, Lauren C Peres, Hamza Hashmi, et al.
Blood Cancer Journal|April 14, 2026
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR studyDoris K Hansen, Danai Dima, Hira Mian, et al.
Blood|July 8, 2026
Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple MyelomaHitomi Hosoya, Arash Velayati, Danai Dima, et al.
Transplantation and Cellular Therapy|June 4, 2024
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World ExperienceJack Khouri, Danai Dima, Hong Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2024
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple MyelomaNico Gagelmann, Danai Dima, Maximilian Merz, et al.
Blood Cancer Journal|August 9, 2023
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapyChristopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, et al.
Pageof 17

Showing results (111-120 of 161) with videos related to

Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2023
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T ConsortiumDoris K Hansen, Surbhi Sidana, Lauren C Peres, et al.
Transplantation and Cellular Therapy|September 19, 2025
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy ConsortiumKaren Sweiss, Charlotte Wagner, Eric Anto, et al.
Haematologica|October 19, 2023
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experienceHamza Hashmi, Doris K Hansen, Lauren C Peres, et al.
Journal of Hematology & Oncology|June 6, 2024
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucelSaurabh Zanwar, Surbhi Sidana, Leyla Shune, et al.
Haematologica|September 21, 2023
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairmentSurbhi Sidana, Lauren C Peres, Hamza Hashmi, et al.
Blood Cancer Journal|April 14, 2026
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR studyDoris K Hansen, Danai Dima, Hira Mian, et al.
Blood|July 8, 2026
Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple MyelomaHitomi Hosoya, Arash Velayati, Danai Dima, et al.
Transplantation and Cellular Therapy|June 4, 2024
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World ExperienceJack Khouri, Danai Dima, Hong Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2024
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple MyelomaNico Gagelmann, Danai Dima, Maximilian Merz, et al.
Blood Cancer Journal|August 9, 2023
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapyChristopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, et al.
Pageof 17